We blog about genomics. We also make a platform for open-source analysis of next generation data in the cloud. Hello.
Yesterday at Festival of Genomics, London, Seven Bridges CEO Deniz Kural joined a panel discussing implementations of graph genomes, alongside Erik Garrison from the Wellcome Trust Sanger Institute and Andy Yates from EMBL-EBI. Great panel talking about #graph #genomes at #GenomicsFest @erikgarrison @denizkural Andrew Yates @FLGenomics pic.twitter.com/4Cxy2CslvT — Adrian Alexa
Ahead of the Festival of Genomics, London, we take a look at what needs to happen in order to make biomedical data truly useful for precision medicine. Have you ever tried to show a friend an article or video that you know they would enjoy, but can’t quite find it?
An emerging characteristic, or hallmark, of cancer cells is their ability to evade destruction by the immune system. While immune surveillance plays a role in controlling tumorigenesis and tumor progression, cancer cells can in turn disable the immune system by secreting immunosuppressive factors or recruiting immunosuppressive cells. Because of this
A revolutionary approach to cancer diagnosis Liquid biopsy, a new technique for tracking down fragments of tumor DNA in the blood, has the potential to revolutionize how cancer is diagnosed and treated. At next week’s Precision Medicine World Congress, Seven Bridges’ Bruce Press will lead the “Update on the Cancer
Late last year we successfully launched the Seven Bridges Platform on the Amazon Web Services (AWS) Frankfurt Region. By making the Platform available on AWS in Frankfurt, we now offer a simpler and faster way for our customers to access and analyze data generated in Europe. With an account on Seven Bridges in
Powered by a wave of next generation sequence data from labs and the clinic, oncology is in the midst of a paradigm shift towards personalized medicine. To the modern cancer biologist, the genomic and transcriptomic features of a patient’s tumor have the potential to function as key guideposts for selecting
The non-trivial matter of optimising compute resources available for your analysis is brought into the spotlight. We discuss when you might benefit from optimising the compute resources available for your analysis as well as how you can achieve this on the Seven Bridges Platform. Examples of effective management of large
As a provider of cloud-based biomedical data analysis services, we are aware that our users compare the long-term storage costs of cloud computing relative to local storage. Amazon Web Services (AWS) recently announced price reductions for both S3 and Glacier cloud storage. Seven Bridges passes through cloud computing and storage
Yesterday we announced the integration of the Seven Bridges Platform for cloud-based biomedical data analysis with SolveBio. This integration enables biotech and pharmaceutical researchers to seamlessly transition from the analysis of large NGS datasets to clinical analysis and interpretation, speeding the progress of their precision medicine initiatives. The integration is available
Seven Bridges is an early adopter and strong supporter of the EU-US Privacy Shield, a framework in which US companies pledge to adhere to EU standards of data protection. Privacy Shield, designed by the US Department of Commerce and the European Commission, allows companies to comply with EU data protection requirements
